Related Experiment Video

Updated: Aug 17, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Ted R Mikuls1, Kenneth G Saag

  • 1University of Nebraska Medical Center and the Omaha VA Medical Center, 983025 NE Med Center, Omaha, NE 68198-3025, USA. tmikuls@unmc.edu.

Current Rheumatology Reports
|May 28, 2005
PubMed

Insights

Gout care is often suboptimal due to limited research. This paper reviews gout management evidence and quality indicators to improve patient safety and care for this common inflammatory arthritis.

Area of Science:

  • Rheumatology
  • Inflammatory Arthritis
  • Gout Management

Background:

  • Gout is a prevalent inflammatory arthritis that remains understudied compared to other rheumatologic conditions.
  • Clinical management strategies for gout have historically lacked robust evidence.
  • Current data indicates that the quality of gout care is frequently suboptimal.

Purpose of the Study:

  • To review the existing evidence supporting current gout management strategies.
  • To examine consensus-building efforts leading to the development of gout management quality indicators.
  • To highlight the necessity for future initiatives focused on enhancing patient safety and care quality in gout management.

Main Methods:

  • Literature review of evidence supporting gout management.
  • Analysis of consensus reports and quality indicator development for gout care.
  • Discussion of current challenges and future directions in gout patient care.

Main Results:

  • Evidence for optimal gout management strategies is still developing.
  • New quality indicators have been established through consensus efforts.
  • Significant gaps remain in ensuring high-quality, safe care for gout patients.

Conclusions:

  • There is a critical need to enhance the evidence base for gout management.
  • The newly developed quality indicators provide a framework for improving care.
  • Future initiatives must prioritize patient safety and quality improvement in gout treatment.

Related Concept Videos

Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.